Hydroxy Saxagliptin (BioDeep_00000711319)
代谢物信息卡片
化学式: C18H25N3O3 (331.189582)
中文名称: 羟基沙格列汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)(CC(C5)(C4)O)O)N
InChI: InChI=1S/C18H25N3O3/c19-6-12-1-11-2-13(11)21(12)15(22)14(20)16-3-10-4-17(23,7-16)9-18(24,5-10)8-16/h10-14,23-24H,1-5,7-9,20H2/t10?,11-,12+,13+,14-,16?,17?,18?/m1/s1
描述信息
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
同义名列表
2 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Ying Peng, Qingqing Chang, Na Yang, Shiyin Gu, Yi Zhou, Lifang Yin, Jiye Aa, Guangji Wang, Jianguo Sun. Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Apr; 1081-1082(?):109-117. doi:
10.1016/j.jchromb.2018.02.007
. [PMID: 29518719] - Priyanka A Shah, Jaivik V Shah, Mallika Sanyal, Pranav S Shrivastav. LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects.
Biomedical chromatography : BMC.
2017 Mar; 31(3):. doi:
10.1002/bmc.3809
. [PMID: 27508356] - Blisse Vakkalagadda, Susan Lubin, Laurie Reynolds, Dan Liang, Alan S Marion, Frank LaCreta, David W Boulton. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
Clinical therapeutics.
2016 Aug; 38(8):1890-9. doi:
10.1016/j.clinthera.2016.07.005
. [PMID: 27491280] - N Batta, N R Pilli, V R Derangula, H B Vurimindi, R Damaramadugu, R P Yejella. A rapid and sensitive LC-MS/MS assay for the determination of saxagliptin and its active metabolite 5-hydroxy saxagliptin in human plasma and its application to a pharmacokinetic study.
Drug research.
2015 Mar; 65(3):133-40. doi:
10.1055/s-0034-1374616
. [PMID: 24941084] - Haiyan Li, Li Yang, Conrad K P Tou, Chirag G Patel, June Zhao. Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
Clinical drug investigation.
2012 Jul; 32(7):465-73. doi:
10.2165/11598760-000000000-00000
. [PMID: 22668067] - Hong Su, David W Boulton, Anthony Barros, Lifei Wang, Kai Cao, Samuel J Bonacorsi, Ramaswamy A Iyer, W Griffith Humphreys, Lisa J Christopher. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Jul; 40(7):1345-56. doi:
10.1124/dmd.112.045450
. [PMID: 22496391] - Aiying Wang, Charles Dorso, Lisa Kopcho, Gregory Locke, Robert Langish, Eric Harstad, Petia Shipkova, Jovita Marcinkeviciene, Lawrence Hamann, Mark S Kirby. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
BMC pharmacology.
2012 Apr; 12(?):2. doi:
10.1186/1471-2210-12-2
. [PMID: 22475049] - Xiaohui Sophia Xu, Roger Demers, Huidong Gu, Lisa J Christopher, Hong Su, Laura Cojocaru, David W Boulton, Mark Kirby, Bruce Stouffer, William G Humphreys, Mark E Arnold. Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Mar; 889-890(?):77-86. doi:
10.1016/j.jchromb.2012.01.033
. [PMID: 22349123] - Liping Zhang, David W Boulton, Marc Pfister. A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Journal of clinical pharmacology.
2012 Jan; 52(1 Suppl):126S-33S. doi:
10.1177/0091270011415627
. [PMID: 22232748] - David W Boulton, Li Li, Ernst U Frevert, Angela Tang, Lorna Castaneda, Nimish N Vachharajani, David M Kornhauser, Chirag G Patel. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Clinical pharmacokinetics.
2011 Apr; 50(4):253-65. doi:
10.2165/11584350-000000000-00000
. [PMID: 21348538] - David J Augeri, Jeffrey A Robl, David A Betebenner, David R Magnin, Ashish Khanna, James G Robertson, Aiying Wang, Ligaya M Simpkins, Prakash Taunk, Qi Huang, Song-Ping Han, Benoni Abboa-Offei, Michael Cap, Li Xin, Li Tao, Effie Tozzo, Gustav E Welzel, Donald M Egan, Jovita Marcinkeviciene, Shu Y Chang, Scott A Biller, Mark S Kirby, Rex A Parker, Lawrence G Hamann. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Journal of medicinal chemistry.
2005 Jul; 48(15):5025-37. doi:
10.1021/jm050261p
. [PMID: 16033281]